Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam Radiotherapy | JoVE Visualize

Area of Science:

Medical Physics
Oncology
Radiochemistry

Background:

Radiopharmaceutical therapy (RPT) presents unique challenges compared to external-beam radiation therapy, including systemic delivery, heterogeneous dose distribution, and low dose rates.
These characteristics complicate traditional radiobiology and established dose-effect relationships, hindering the definition of effective dose constraints.
Current approaches struggle to adequately address the complexities of RPT, necessitating novel strategies for dose optimization and toxicity management.

Purpose of the Study:

To highlight the challenges in applying conventional radiobiology and dose-effect relationships to radiopharmaceutical therapy.
To emphasize the critical need for personalized dosimetry in optimizing RPT efficacy and minimizing toxicity.
To advocate for the development of RPT-specific models and clinical trial designs that account for inherent biological and physical complexities.

Main Methods:

Review and synthesis of current understanding of radiopharmaceutical therapy radiobiology and dosimetry.
Analysis of the limitations of external-beam radiation therapy paradigms when applied to RPT.
Identification of key factors for improved RPT treatment planning, including spatial heterogeneity, radiosensitivity, and patient-specific parameters.

Main Results:

Radiopharmaceutical therapy's distinct features (systemic delivery, heterogeneous dose, low dose rate) challenge existing radiobiological models and dose constraints.
Personalized dosimetry is identified as a key strategy for optimizing therapeutic outcomes in RPT.
The need for RPT-specific models that integrate spatial heterogeneity, radiosensitivity, and patient factors is underscored.

Conclusions:

Conventional radiobiology and dose-effect relationships are insufficient for radiopharmaceutical therapy.
Integrating personalized dosimetry into clinical trials is essential for improving the therapeutic index of RPT.
Future research must focus on developing RPT-specific models and trial designs to enhance treatment efficacy and limit toxicity.